ScreenerHero

BNTCBenitec Biopharma Inc.

NAS · US · Healthcare · Biotechnology · benitec.com
13.48USD+0.75%Mkt Cap: 463.10M $P/E: —

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap463.10M $
Enterprise Value263.06M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-37.92M $
Revenue/Share—
Last Price13.48 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS08205P1003
Valuation
P/E (Trailing)—
P/E (Forward)-1.38
PEG—
EV/EBITDA-5.65
EV/Revenue—
P/S—
P/B2.44
EPS (TTM)-0.91
EPS (Forward)-9.42
52W Range
9.85053% of range16.76
52W High16.76 USD
52W Low9.850 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-38.97%
ROA-38.07%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.59M $
CapEx (TTM)18.00K $
FCF Margin—
FCF Yield-1.54%
Net Debt-183.88M $
Net Debt/EBITDA3.95
Balance Sheet
Debt/Equity0.01
Current Ratio56.82
Quick Ratio56.43
Book Value/Sh5.337 USD
Cash/Share5.378 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 18, 2019
Splits
Last Split1:17
Split DateJul 26, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.17 USD
Upside (mean)+79.3%
Target Range16.00 USD – 32.00 USD
$16.00+79.3% to mean$32.00
# Analysts6
Ownership
Shares Out.34.35M
Float17.93M
Insiders2.55%
Institutions100.45%
Short Interest
Short Ratio24.5d
Short % Float11.06%
Short % Out.6.25%
Shares Short2.15M
Short (prev mo.)2.23M
Technical
SMA 5012.50 (+7.8%)
SMA 20012.16 (+10.8%)
Beta0.26
S&P 52W Chg18.16%
Avg Vol (30d)126.28K
Avg Vol (10d)264.32K
Technical Indicators
RSI (14)59.8
MACD0.2507
MACD Signal0.1792
MACD Hist.+0.0715
BB Upper14.07 USD
BB Middle12.54 USD
BB Lower11.01 USD
BB Width24.42%
ATR (14)0.7889 USD
Vol Ratio (20d)1.06x